

First Committee Meeting, January 17, 2013 - Alprolix

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448

Committee Meeting Minutes

Our Reference: BL STN 125444/0

MEETING DATE: January 17, 2013, 3:00 – 3:30 p.m., Rm. 400N

SUBJECT: First Committee Meeting

FROM: Edward Thompson
Regulatory Project Manager

PRODUCT: Coagulation Factor IX (Recombinant), Fc fusion protein [rFIXFc]

INDICATION: For control and prevention of bleeding episodes; routine prophylaxis to prevent or reduce the frequency of bleeding episodes; perioperative management (surgical prophylaxis) in patients with Hemophilia B

Summary of the Meeting

The first committee meeting for BL STN 125444/0, original biologics license application (BLA) from Biogen Idec for Coagulation Factor IX (Recombinant), Fc fusion protein, was held on January 17, 2013, from 3:00 – 3:30 p.m. It was confirmed that a reviewer had been assigned to review each section of the application. Table 1 lists review committee members.

Table 1: Review Committee

Discipline	Reviewer	Branch/Contact
RPM	Edward Thompson	DBA/RPMB/x9167

Discipline	Reviewer	Branch/Contact
Chair/Product CMC	Nancy Kirschbaum	DH/LH/x3893
Product CMC	Andrey Sarafanov	DH/LH/x4025
Product CMC	Ze Peng	DH/LH/x9219
Pharmacology/Toxicology	La'Nissa Brown	DH/x3897
Clinical Pharmacology	Carl-Michael Staschen	DH/x6148
Clinical Safety and Efficacy	Stephanie Omokaro, Nisha Jain	DH/CRB/x9052 DH/CRB/x6110
CMC GMP	Ellen Huang	OCBQ/DMPQ/x7199
Labeling	Loan Nguyen	OCBQ/DCM/APLB/x6333
Bioresearch Monitoring	Anthony Hawkins	OCBQ/DIS/BMB/x6338
Biostatistics/Epidemiology	Bethany Baer	OBE/DE/AEB/x4061
Biostatistics	Judy Li	OBE/DB/TEB/x3596
Quality Control	Catherine Poole	OCBQ/DBSQC/301.594.6272

BLA 125444/0 was submitted on December 28, 2012. The review schedule and milestones for BLA 125444/0 under PDUFA V were discussed. Biogen Idec requested Priority Review under its Fast Track Designation. The review committee made the decision to deny Biogen's request for Priority Review because there is an FDA licensed, safe and efficacious recombinant coagulation factor IX product commercially available that is used for the same clinical indications. The 12 month review schedule for BLA 125444/0 is provided in Table 2

Table 2: BLA 125444/0 review schedule

Milestone	Target Date
DCC Receipt Date	December 28, 2012
Complete regulatory filing review; Assign review committee	January 7, 2013
Acknowledge receipt; Establish review schedule	January 11, 2013
First Committee Meeting	January 18, 2013 (met Jan. 17)
30 day late components due	January 25, 2013
Filing Meeting	February 11, 2013
Send Filing Determination Letter	February 26, 2013
Deficiencies Identified Letter	March 12, 2013
Proprietary Name Review	March 28, 2013
Request initial labeling review	May 30, 2013
Mid-Cycle Meeting	June 13, 2013 (scheduled June 11)
Mid-cycle communication with applicant	June 27, 2013
Complete Discipline Review (Primary)	Aug. 2, 2013

Milestone	Target Date
Complete Discipline Reviews (Secondary)	August 16, 2013
Send Discipline Review memos as completed	
Send Late Cycle/ Advisory Committee briefing package	August 30, 2013
External Late Cycle Meeting	September 12, 2013
Advisory Committee Meeting, if needed	September 27, 2013
Promotional Labeling Review	September 27, 2013
Complete Inspection Reports	October 28, 2013
PeRC Meeting	November 15, 2013
Circulate draft press release	November 28, 2013
Complete PMC Study, Labeling Review, Review Addenda	November 28, 2013
Complete Supervisory Review	November 28, 2013
Request Compliance Check, Lot Release Clearance	December 13, 2013
Send Press Release to OCTMA	December 13, 2013
T-minus date	December 13, 2013
Send FDA Action Letter	December 27, 2013

Although, it was determined that the submission was essentially complete, Bethany Baer noted that absence of a Pharmacovigilance Plan and Ellen Huang noted missing facilities and establishment information. Two information requests for the missing information were drafted and sent to Biogen Idec..

It was determined tentatively that an advisory committee meeting would not be needed because this is a recombinant product and there are no controversial issues for advisory committee decision. The need for an advisory committee meeting will be determined by mid-cycle.

Anthony Hawkins proposed BiMo inspections at four U.S. clinical sites that participated in the Phase 3, B-LONG clinical study, covering approximately 25 of the 35 total subjects enrolled at U.S. sites. He plans to submit inspection requests within the next 30 days. Nisha Jain also recommended looking at sites that performed PK studies.

Ellen Huang introduced the two sites where product manufacture occurs: (1) Biogen Idec in -----(b)(4)----- for drug substance and (2) -----(b)(4)----- contract manufacturer for drug product and diluent. Ellen stated that there was justification to waive the pre-license inspections based on recent coverage by CDER inspection teams. Ellen did note that -----(b)(4)----- had received an Official Action Indicated (OAI) classification from the most recent inspection of diluent manufacture. Nancy Kirschbaum expressed the opinion that a pre-license inspection should be conducted at least at -(b)(4)- for drug substance based on the fact that this was a novel product with a complex manufacturing process by a

company with which CBER had no experience. Ellen indicated she would discuss this further with her management.

END